Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
The U.S. film industry has a worldwide influence and following. Hollywood, a district in central Los Angeles, the nation's second-most populous city, is also metonymous for the American filmmaking industry. The major film studios of the United States are the primary source of the most commercially successful movies selling the most tickets in the world. Largely centered in the New York City region from its beginnings in the late 19th century through the first decades of the 20th century, the U.S. film industry has since been primarily based in and around Hollywood. Nonetheless, American film companies have been subject to the forces of globalization in the 21st century, and an increasing number of films are made elsewhere. The Academy Awards, popularly known as "the Oscars", have been held annually by the Academy of Motion Picture Arts and Sciences since 1929, and the Golden Globes have been held annually since January 1944. The industry peaked in what is commonly referred to as the "Golden Age of Hollywood", from the early sound period until the early 1960s, with screen actors such as John Wayne and Marilyn Monroe becoming iconic figures. In the 1970s, "New Hollywood", or the "Hollywood Renaissance", was defined by grittier films influenced by French and Italian realist pictures of the post-war period. The 21st century has been marked by the rise of American streaming platforms, which came to rival traditional cinema.
The practice of medicine in the United States is currently in a major transition. This transition is due to many factors, but primarily because of the implementation and integration of health technologies into healthcare. In recent years, the widespread adoption of electronic health records (EHR) has greatly impacted healthcare. In his book The Digital Doctor: Hope, Hype, and Harm at the Dawn of Medicine's Computer Age, Robert Wachter aims to inform readers about this transition. Wachter states that there will be fewer hospitals in the future, and due to the advancement of technologies, people will be more likely to go to hospitals for major surgeries or critical illness. In the future, nurse call buttons will not be needed in hospitals. Instead, robots will deliver medication, take care of patients, and administer the system. In addition, the electronic health record will look different. Healthcare providers will be able to enter the notes via speech-to-text transcriptions in real-time. Wachter stated that information will be edited collaboratively across the patient-care team to improve the quality. Also, natural language processing will be more developed to help parse out keywords. In the future, patient data will reside in the cloud, and patients as well as authorized providers and individuals will be able to access their data from any device or location. Big data analysis will constantly be improving. Artificial intelligence and machine learning will be constantly improving and developing as it receives new data.
Atenolol is a beta blocker medication primarily used to treat high blood pressure and heart-associated chest pain. Although used to treat high blood pressure, it does not seem to improve mortality in those with the condition. Other uses include the prevention of migraines and treatment of certain irregular heart beats. It is taken orally (by mouth) or by intravenous injection (injection into a vein). It can also be used with other blood pressure medications. Common side effects include feeling tired, heart failure, dizziness, depression, and shortness of breath. Other serious side effects include bronchial spasm. Use is not recommended during pregnancy and alternative drugs are preferred when breastfeeding. It works by blocking β1-adrenergic receptors in the heart, thus decreasing heart rate, force of heart beats, and blood pressure. Atenolol was patented in 1969 and approved for medical use in 1975. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 75th most commonly prescribed medication in the United States, with more than 9 million prescriptions.
=== Atherosclerosis === Rapamycin can accelerate degradation of oxidized LDL cholesterol in endothelial cells, thereby lowering the risk of atherosclerosis. Oxidized LDL cholesterol is a major contributor to atherosclerosis.
Sources: en.wikipedia.org
APEC Business Travel Card (ABTC): The APEC Business Travel Card, or ABTC, is an expedited border control programme for business travellers from APEC economies (excluding Canada and America). It provides visa exemptions and access to expedited border control facilities. ABTC holders are eligible for expedited border control at Canadian airports but not for any visa exemptions. ABTCs are generally issued only to citizens of APEC member countries; however, Hong Kong issues them to Permanent Residents who are not Chinese citizens, a category primarily consisting of British, Indian, and Pakistani citizens. The use of ABTCs in China is restricted due to the One Country, Two Systems and One China policies. Chinese nationals from Hong Kong, Macau, and the Republic of China are required to use special internal travel documents to enter the mainland. Similar restrictions apply to the use of ABTC by Chinese citizens from other regions entering areas administered by the Republic of China. (see: Internal border controls). Australia: SmartGates located at major Australian airports, allowing Australian ePassport holders and ePassport holders of several other countries to clear immigration controls more rapidly, and to enhance travel security by performing passport control checks electronically. SmartGate uses facial recognition system to verify the traveller's identity against the data stored in the chip in their biometric passport, as well as checking against immigration databases.
pinocytosis A form of endocytosis in which liquid and suspended solids from the extracellular environment are captured in inward invaginations of the cell membrane which then "bud off" into enclosed vesicles in the cytoplasm. The contents of these vesicles are then passed to organelles such as endosomes by fusion of the vesicular and organellar membranes. Pinocytosis is the predominant form of endocytosis occurring in most cells, such that the term is often used interchangeably with endocytosis as a whole.
== History == The MHD description of electrically conducting fluids was first developed by Hannes Alfvén in a 1942 paper published in Nature titled "Existence of Electromagnetic–Hydrodynamic Waves", which outlined his discovery of what are now known as Alfvén waves. Alfvén initially referred to these waves as "electromagnetic–hydrodynamic waves"; however, in a later paper, he noted, "As the term 'electromagnetic–hydrodynamic waves' is somewhat complicated, it may be convenient to call this phenomenon 'magneto–hydrodynamic' waves."
Sources: en.wikipedia.org
Royal Navy hardtack during Queen Victoria's reign was made by machine at the Royal Clarence Victualing Yard at Gosport, Hampshire, stamped with the Queen's mark and the number of the oven in which it was baked. When machinery was introduced into the process, the dough was thoroughly mixed and rolled into sheets about two yards (6 ft; 72 in; 183 cm) long and one yard (3 ft; 36 in; 91 cm) wide, which were then stamped in one stroke into about sixty hexagonal shaped biscuits. The hexagonal shape saved material and time and made them easier to pack compared to the traditional circular shaped biscuit. Hardtack remained an important part of the Royal Navy sailor's diet until the introduction of canned foods; canned meat was first marketed in 1814, and preserved beef in tins was officially introduced to the Royal Navy rations in 1847. As early as the Spanish–American War in 1898, some military hardtack was used by service members in etching or writing notes, often commemorating events or coined with phrases of the time.
Additionally, beta-cell function has to be interpreted in light of the prevailing insulin sensitivity. This is necessary since the beta cell mass is adjusted as required by dynamical compensation, giving rise to a hyperbolic relationship between insulin sensitivity and beta cell function. In the state of insulin resistance beta cells proliferate and their secretory capacity subsequently rises. One possibility to address this relation is to resort to a normalization of beta cell function based on a disposition metric. The disposition index, calculated as product of insulin sensitivity and beta cell function, is assumed to be a constant during the development of insulin resistance. It is generally assumed that the glucose tolerance of an individual is related to the disposition index. In this model, different values of glucose tolerance are represented by different hyperbolas, so that within one hyperbola the product of insulin sensitivity and beta cell function remains a constant. In summary, to provide a meaningful mechanistic explanation of insulin-glucose homeostasis, beta cell function and insulin sensitivity have to be assessed simultaneously and it is necessary to interpret all observations in the context of insulin sensitivity or resistance.
=== Hypoaldosteronism === An ACTH stimulation test for aldosterone can help in determining the cause of hypoaldosteronism, with a low aldosterone response indicating a primary hypoaldosteronism of the adrenals, while a large response indicating a secondary hypoaldosteronism. The most common cause of this condition (and related symptoms) is Addison's disease; it is typically treated by fludrocortisone, which has a much longer persistence (1 day) in the bloodstream.
Latin American leaders, including the presidents of Colombia, Guatemala and Mexico, have called for debate about legalizing and regulating aspects of drug production, trade or use. Some Latin leaders are discussing the need to experiment further with decriminalizing possession of drugs. Lawmakers are also proposing to scrap jail terms for growing coca and cannabis. As some Latin American leaders call for legalization of narcotics, Peru, a leading coca grower, remains opposed.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.